The North America PCR Technologies Market is experiencing robust growth driven by increasing demand for advanced molecular diagnostics, the rise of infectious diseases, and the adoption of innovative PCR technologies. Industry giants and regional players are heavily investing in R&D, strategic partnerships, and product launches, fueling the market trajectory from 2020 to 2035.
The economic impact of tariffs on "North America PCR Technologies Market".
Market Growth Drivers
Expansion of molecular diagnostics for infectious diseases: The COVID-19 pandemic has significantly boosted the requirement for advanced PCR-based diagnostics. Companies like Thermo Fisher Scientific and Bio-Rad Laboratories have ramped up their production capacities and expanded their PCR test portfolios, tailoring products for pathogen detection and variant identification. This surge in demand is projected to have a lasting impact, as awareness around rapid and accurate diagnostics remains high in the public health sector.
Integration of automation and digital PCR: The evolution of automated and digital PCR systems is enhancing lab efficiency, accuracy, and throughput. Becton, Dickinson and Company (BD) recently launched BD MAX™ System advancements, optimizing workflow in clinical laboratories. These technological advancements allow for reduced human error, early disease detection, and high-volume processing of clinical samples, spurring adoption across research and healthcare facilities.
Market Trends
Growing adoption of point-of-care PCR devices: Leading players like Abbott and Cepheid are focusing on miniaturized, rapid, and portable PCR platforms for point-of-care settings. These platforms, such as Abbott’s ID NOW™ and Cepheid’s GeneXpert®, have played a crucial role in decentralizing testing, especially during public health emergencies, and are continuing to see widespread deployment in pharmacies, clinics, and remote healthcare settings.
Rising investment in multiplex and high-throughput PCR: The need for simultaneous detection of multiple pathogens and genetic markers has accelerated the adoption of multiplex and high-throughput PCR technologies. Companies such as QIAGEN have introduced tests capable of detecting several respiratory viruses in a single run, helping laboratories conserve resources and reduce turnaround times for large-volume testing amid seasonal outbreaks and pandemics.
Market Opportunities
Expansion into oncology and genetic diseases: Companies like Roche are developing advanced PCR assays for early cancer detection and genetic disorder screening, opening lucrative growth avenues in personalized medicine and precision diagnostics.
Stringent regulatory approvals benefiting established players: The challenging landscape in obtaining regulatory approval for new PCR devices allows established manufacturers like Thermo Fisher Scientific to cement their market positions by leveraging their compliance track record and extensive distribution networks.
North America PCR Technologies Market Revenue (USD Million), 2020-2035
The chart illustrates consistent revenue growth in the North America PCR Technologies Market from 2020 to 2035. The market was valued at USD 4,600 Million in 2020 and is projected to reach approximately USD 14,800 Million by 2035, reflecting a CAGR of 9.8%. This upward trend is fueled by innovations in digital and point-of-care PCR, increased adoption for infectious disease diagnostics, and expansion into oncology and personalized medicine. Notable jumps in revenue are observed post-2023, mainly driven by post-pandemic investments and robust pipelines of new PCR-based diagnostic products.
North America PCR Technologies Market by Regional Share (%) in 2025
The 2025 market share distribution chart indicates the United States dominates with 74% of North America's PCR Technologies Market revenue, benefiting from advanced healthcare infrastructure and high R&D investments. Canada follows with 18%, driven by increased government healthcare spending and diagnostics innovation. Mexico and the Rest of North America collectively account for 8%, reflecting emerging demand and expanding diagnostic capacity in those regions.
Recent Market Developments
In April 2024, Thermo Fisher Scientific announced the launch of the Applied Biosystems QuantStudio Absolute Q AutoRun Real-Time PCR System in North America. This new platform is designed for high-throughput laboratories and features enhanced automation and user-friendly interfaces to streamline complex diagnostic workflows, targeting hospital networks, academic centers, and large reference labs seeking increased operational efficiency.
In May 2024, Roche received FDA Emergency Use Authorization (EUA) extension for its cobas® SARS-CoV-2 & Influenza PCR Test, expanding RSV coverage and multiplex capabilities. This move strengthens Roche's infectious disease portfolio at a time when multiplex respiratory testing is in high demand for both clinical and public health monitoring in the United States and Canada.
In March 2024, Abbott announced a new partnership with Walgreens to deploy the ID NOW™ PCR Molecular Platform in hundreds of pharmacy clinics across North America. This collaboration aims to make rapid, on-site molecular diagnostics more accessible to consumers, supporting Abbott’s strategy to lead in decentralized and retail healthcare delivery segments.
Press Releases